Clinical Trial

A Clinical Study of MK-8527 in Healthy Adult Participants (MK-8527-014)

Completed Phase 1
View on ClinicalTrials.gov →
Summary
Researchers are looking for new medicines to prevent Human Immunodeficiency Virus Type 1 (HIV-1) infection. HIV-1 is the most common type of HIV, which is a virus that attacks cells of the immune system. Medicines to prevent HIV-1 infection are called pre-exposure prophylaxis (PrEP). Some people may have trouble following a PrEP plan because it involves either taking medicine everyday by mouth or getting injections (shots) often. MK-8527 is a study medicine designed to prevent HIV-1 infection. MK-8527 is different from standard (usual) PrEP because it is taken once a month, by mouth, as a tablet. The goal of this study is to learn if taking a higher-than-normal dose of MK-8527 increases the QT interval (a measure of heart rhythm) by a certain amount.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2025-07-03; most recent amendment 2026-01-28.
Status change: Active, Not Recruiting → Completed 2026-01-28
Status change: Recruiting → Active, Not Recruiting 2025-10-07
Status change: Not Yet Recruiting → Recruiting 2025-08-20
Trial Details
NCT Number NCT07063238
Lead Sponsor Merck Sharp & Dohme LLC
Conditions Healthy
Enrollment 42 participants
Start Date 2025-08-12
Primary Completion 2025-12-06 (estimated)
Study Completion 2025-12-29 (estimated)
Updated on ClinicalTrials.gov 2026-01-29